课题基金 / 基金详情

Intracellular localization of Wilson disease protein(ATP7B), a copper-transporting ATPase.

Intracellular localization of Wilson disease protein(ATP7B), a copper-transporting ATPase.
威尔逊病蛋白 (ATP7B)(一种铜转运 ATP 酶)的细胞内定位。
批准号:
12670535
负责人:
HARADA Masaru
金额:
$1.34万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

HARADA Masaru的其他基金

相似基金

相关文献

中文摘要
翻译
Wilson病是一种遗传性疾病,其特征是由于肝细胞的胆汁铜排泄缺陷而导致铜在体内蓄积。通过在培养细胞中表达绿色荧光蛋白标记的肝豆状核变性基因产物ATP 7 B(GFP-ATP 7 B),研究其在细胞内的定位。通过荧光显微镜观察细胞内细胞器。GFP-ATP 7 B与晚期内体标记共定位,但不与高尔基体和溶酶体标记共定位。在Wilson病患者中已经记录了各种突变。临床表现差异很大的患者之间,但是,很少有信息的基因型-表型相关性。我们通过表达GFP标记的突变体,研究了ATP 7 B突变体His 1069 G1和突变体Asp 1270 Ser的分布。Asp 1270 Ser突变体定位于晚期内体,而His 1069 Gln突变体不定位于晚期内体,在胞浆中被蛋白酶体降解。此外,His 1069 Gl在微管组织中心形成由降解产物和中间产物组成的攻击体。电镜下可见类似于马洛里小体的侵袭小体。ATP 7 B定位于晚期内涵体在铜耗尽和铜负载条件。ATP 7 B似乎将铜从细胞质转运到晚期内体中,并且铜可以通过溶酶体排泄到胆汁中。由突变的ATP 7 B引起的铜掺入晚期内体的干扰必须是Wilson病的主要缺陷。ATP 7 B突变体的不同蛋白质特性可以部分解释Wilson病患者的临床谱的多样性。
英文摘要
Wilson disease is a genetic disorder characterized by the accumulation of copper in the body due to a defect of biliary copper excretion from hepatocytes. The intracellular localization of Wilson disease gene product, ATP7B, was investigated by expressing ATP7B tagged with green fluorescent protein (GFP)(GFP-ATP7B) in cultured cells. Intracellular organelles were visualized by fluorescence microscopy. GFP-ATP7B colocalized with the late endosome markers, but not with markers for the Golgi apparatus and lysosomes. Various mutations have been documented in patients with Wilson disease. The clinical manifestations vary greatly among the patients, however, there is little information on the genotype-phenotype correlation. We investigated the distribution of a common ATP7B mutant His 1069Gl and a mutant Asp l270Ser by expressing the mutants tagged with GFP. While Asp l270Ser mutant localized in the late endosomes, His 1069Gln mutant did not locate in the late endosomes and was degraded by the proteasomes in the cytoplasm. Furthermore, His 1069Gl formed aggresomes composed of the degradates and intermediate filamentsat the microtubule-organizing center. These aggresomes were similar to Mallory bodies on electron microscopy. ATP7B localized in the late endosomes in both copper-depleting and copper-loaded conditions. ATP7B seems to translocate copper from the cytosol into the late endosomes, and copper may be excreted to bile via lysosomes. The disturbed incorporation of copper into the late endosomes caused by mutated ATP7B must be the main defect in Wilson disease. The different protein properties of ATP7B mutants may in part explain the variety of clinical spectrums in patients with Wilson disease.
期刊论文(29)
专著(0)
科研奖励(0)
会议论文
山田剛太郎: "肝と金属代謝-病態と治療をめぐる最近の知見-"肝胆膵. 41・3. 427-442 (2000)
Gotaro Yamada:“肝脏和金属代谢 - 有关病理学和治疗的最新发现”肝胆胰 41・3(2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
原田 大: "ウイルソン病蛋白(ATP7B)は肝細胞後期エンドゾームに存在する"肝サイトスケレトン研究会誌. 11. 23-25 (2001)
Dai Harada:“威尔逊病蛋白(ATP7B)存在于肝细胞的晚期内体中”肝脏细胞骨架研究学会杂志11. 23-25(2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaru Harada et al.: "Mallory bodies, like the mutant of ATP7B seen in Wilson's disease, areaggresomes. Reply"Gastroenterology. 121. 1264-1266 (2001)
原田正等人:“马洛里小体,就像威尔逊病中看到的 ATP7B 突变体,是聚集体。回复”胃肠病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaru Harada et al.: "A mutation of the Wilson disease protein, ATP7B, is degraded in the proteasomes and forms protein aggregates"Gastroenterology. 120. 967-974 (2001)
Masaru Harada 等人:“威尔逊病蛋白 ATP7B 的突变在蛋白酶体中被降解并形成蛋白聚集体”胃肠病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
26
    Role of autophagy in liver diseases associated with stress
    Mechanisms of Mallory body formation and elimination in hepatocytes
    Biological significance of the expression of a Wilson disease mutant protein
    • 批准号:
      14570528
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.5万
    • 财政年份:
      2002
    • 负责人:
      HARADA Masaru
    • 依托单位:
    国内基金
    海外基金
    “肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
    • 批准号:
      82370902
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      田景琰
    • 依托单位:
    以胆酸为载体的肝靶向阿德福韦前体药物的研究